Please use this identifier to cite or link to this item:
|Title:||Biliary excretion and conjugation of diacid angiotensin-converting enzyme inhibitors.||Austin Authors:||Drummer, Olaf H;Nicolaci, J;Iakovidis, D||Affiliation:||Melbourne University, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia||Issue Date:||1-Mar-1990||Publication information:||The Journal of Pharmacology and Experimental Therapeutics; 252(3): 1202-6||Abstract:||The metabolism and biliary excretion of the diacid angiotensin-converting enzyme inhibitors enalapril, lisinopril, perindopril and ramipril have been studied in an isolated perfused rat liver model. Inhibitors were presented to the livers at a dose of 100 micrograms. The hepatic clearance of lisinopril was very low (0.072 ml/min) and was hardly excreted into the bile. The clearances of enalapril, perindopril and ramipril were higher at 0.63, 0.87 and 9.9 ml/min, respectively, and were excreted into bile. The amounts of ester prodrugs excreted in bile were 4.0, 6.1 and 14%, respectively, whereas the diacid forms were excreted to the extent of 46, 27 and 71% of the administered dose, respectively, over 4 hr. Glucuronide metabolites were only detected in bile in significant concentrations for perindopril and ramipril. Base hydrolysis of the perfusate samples showed that lisinopril was not significantly metabolized to conjugates and that little metabolism of enalapril occurred other than rapid conversion to the diacid form. However, both perindopril and ramipril were extensively metabolized beyond the diacid form. These differences in hepatic handling can in part be explained by their octanol-buffer partition coefficients but may also be related to the introduction of a bicyclic ring in perindopril and ramipril which increases their ability to be metabolized and excreted into bile. These differences in hepatic handling of angiotensin-converting enzyme are likely to influence their clinical usefulness, particularly in renal and hepatic disease.||Gov't Doc #:||2319468||URI:||https://ahro.austin.org.au/austinjspui/handle/1/11617||Journal:||The Journal of pharmacology and experimental therapeutics||URL:||https://pubmed.ncbi.nlm.nih.gov/2319468||Type:||Journal Article||Subjects:||Angiotensin-Converting Enzyme Inhibitors.analysis.pharmacokinetics
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 7, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.